189 related articles for article (PubMed ID: 29760015)
1. Novel genomic findings in multiple myeloma identified through routine diagnostic sequencing.
Ryland GL; Jones K; Chin M; Markham J; Aydogan E; Kankanige Y; Caruso M; Guinto J; Dickinson M; Prince HM; Yong K; Blombery P
J Clin Pathol; 2018 Oct; 71(10):895-899. PubMed ID: 29760015
[TBL] [Abstract][Full Text] [Related]
2. A Next-Generation Sequencing Strategy for Evaluating the Most Common Genetic Abnormalities in Multiple Myeloma.
Jiménez C; Jara-Acevedo M; Corchete LA; Castillo D; Ordóñez GR; Sarasquete ME; Puig N; Martínez-López J; Prieto-Conde MI; García-Álvarez M; Chillón MC; Balanzategui A; Alcoceba M; Oriol A; Rosiñol L; Palomera L; Teruel AI; Lahuerta JJ; Bladé J; Mateos MV; Orfão A; San Miguel JF; González M; Gutiérrez NC; García-Sanz R
J Mol Diagn; 2017 Jan; 19(1):99-106. PubMed ID: 27863261
[TBL] [Abstract][Full Text] [Related]
3. Longitudinal analysis of 25 sequential sample-pairs using a custom multiple myeloma mutation sequencing panel (M(3)P).
Kortüm KM; Langer C; Monge J; Bruins L; Zhu YX; Shi CX; Jedlowski P; Egan JB; Ojha J; Bullinger L; Kull M; Ahmann G; Rasche L; Knop S; Fonseca R; Einsele H; Stewart AK; Braggio E
Ann Hematol; 2015 Jul; 94(7):1205-11. PubMed ID: 25743686
[TBL] [Abstract][Full Text] [Related]
4. Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma.
Walker BA; Boyle EM; Wardell CP; Murison A; Begum DB; Dahir NM; Proszek PZ; Johnson DC; Kaiser MF; Melchor L; Aronson LI; Scales M; Pawlyn C; Mirabella F; Jones JR; Brioli A; Mikulasova A; Cairns DA; Gregory WM; Quartilho A; Drayson MT; Russell N; Cook G; Jackson GH; Leleu X; Davies FE; Morgan GJ
J Clin Oncol; 2015 Nov; 33(33):3911-20. PubMed ID: 26282654
[TBL] [Abstract][Full Text] [Related]
5. Multiple Myeloma Genomics: A Systematic Review.
Weaver CJ; Tariman JD
Semin Oncol Nurs; 2017 Aug; 33(3):237-253. PubMed ID: 28729121
[TBL] [Abstract][Full Text] [Related]
6. The spectrum of somatic mutations in monoclonal gammopathy of undetermined significance indicates a less complex genomic landscape than that in multiple myeloma.
Mikulasova A; Wardell CP; Murison A; Boyle EM; Jackson GH; Smetana J; Kufova Z; Pour L; Sandecka V; Almasi M; Vsianska P; Gregora E; Kuglik P; Hajek R; Davies FE; Morgan GJ; Walker BA
Haematologica; 2017 Sep; 102(9):1617-1625. PubMed ID: 28550183
[TBL] [Abstract][Full Text] [Related]
7. A multiple myeloma-specific capture sequencing platform discovers novel translocations and frequent, risk-associated point mutations in IGLL5.
White BS; Lanc I; O'Neal J; Gupta H; Fulton RS; Schmidt H; Fronick C; Belter EA; Fiala M; King J; Ahmann GJ; DeRome M; Mardis ER; Vij R; DiPersio JF; Levy J; Auclair D; Tomasson MH
Blood Cancer J; 2018 Mar; 8(3):35. PubMed ID: 29563506
[TBL] [Abstract][Full Text] [Related]
8. Recurrent mutations of MAPK pathway genes in multiple myeloma but not in amyloid light-chain amyloidosis.
Kim SJ; Shin HT; Lee HO; Kim NK; Yun JW; Hwang JH; Kim K; Park WY
Oncotarget; 2016 Oct; 7(42):68350-68359. PubMed ID: 27634910
[TBL] [Abstract][Full Text] [Related]
9. Genomic Aberrations in Multiple Myeloma.
Manier S; Salem K; Glavey SV; Roccaro AM; Ghobrial IM
Cancer Treat Res; 2016; 169():23-34. PubMed ID: 27696256
[TBL] [Abstract][Full Text] [Related]
10. Targeted sequencing using a 47 gene multiple myeloma mutation panel (M(3) P) in -17p high risk disease.
Kortüm KM; Langer C; Monge J; Bruins L; Egan JB; Zhu YX; Shi CX; Jedlowski P; Schmidt J; Ojha J; Bullinger L; Liebisch P; Kull M; Champion MD; Van Wier S; Ahmann G; Rasche L; Knop S; Fonseca R; Einsele H; Stewart AK; Braggio E
Br J Haematol; 2015 Feb; 168(4):507-10. PubMed ID: 25302557
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive characterization of the mutational landscape in multiple myeloma cell lines reveals potential drivers and pathways associated with tumor progression and drug resistance.
Vikova V; Jourdan M; Robert N; Requirand G; Boireau S; Bruyer A; Vincent L; Cartron G; Klein B; Elemento O; Kassambara A; Moreaux J
Theranostics; 2019; 9(2):540-553. PubMed ID: 30809292
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive detection of recurring genomic abnormalities: a targeted sequencing approach for multiple myeloma.
Yellapantula V; Hultcrantz M; Rustad EH; Wasserman E; Londono D; Cimera R; Ciardiello A; Landau H; Akhlaghi T; Mailankody S; Patel M; Medina-Martinez JS; Arango Ossa JE; Levine MF; Bolli N; Maura F; Dogan A; Papaemmanuil E; Zhang Y; Landgren O
Blood Cancer J; 2019 Dec; 9(12):101. PubMed ID: 31827071
[TBL] [Abstract][Full Text] [Related]
13. A DNA target-enrichment approach to detect mutations, copy number changes and immunoglobulin translocations in multiple myeloma.
Bolli N; Li Y; Sathiaseelan V; Raine K; Jones D; Ganly P; Cocito F; Bignell G; Chapman MA; Sperling AS; Anderson KC; Avet-Loiseau H; Minvielle S; Campbell PJ; Munshi NC
Blood Cancer J; 2016 Sep; 6(9):e467. PubMed ID: 27588520
[TBL] [Abstract][Full Text] [Related]
14. Advances in the pathogenesis and diagnosis of multiple myeloma.
Chesi M; Bergsagel PL
Int J Lab Hematol; 2015 May; 37 Suppl 1():108-14. PubMed ID: 25976968
[TBL] [Abstract][Full Text] [Related]
15. Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy.
Lohr JG; Stojanov P; Carter SL; Cruz-Gordillo P; Lawrence MS; Auclair D; Sougnez C; Knoechel B; Gould J; Saksena G; Cibulskis K; McKenna A; Chapman MA; Straussman R; Levy J; Perkins LM; Keats JJ; Schumacher SE; Rosenberg M; ; Getz G; Golub TR
Cancer Cell; 2014 Jan; 25(1):91-101. PubMed ID: 24434212
[TBL] [Abstract][Full Text] [Related]
16. [Gene Mutation and Overexpression of Newly Diagnosed Multiple Myeloma Patients].
Fan Y; Wang SJ; Liu YF; Wang C; Li YF; Wang WQ; Hao QQ; Zhang DF; Li YM; Sun H; Guo R; Chen SQ; Xie XS; Li T; Wan DM; Jiang ZX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Feb; 30(1):166-169. PubMed ID: 35123621
[TBL] [Abstract][Full Text] [Related]
17. The prognostic significance of cytogenetics and molecular profiling in multiple myeloma.
Sawyer JR
Cancer Genet; 2011 Jan; 204(1):3-12. PubMed ID: 21356186
[TBL] [Abstract][Full Text] [Related]
18. The long tail of molecular alterations in non-small cell lung cancer: a single-institution experience of next-generation sequencing in clinical molecular diagnostics.
Fumagalli C; Vacirca D; Rappa A; Passaro A; Guarize J; Rafaniello Raviele P; de Marinis F; Spaggiari L; Casadio C; Viale G; Barberis M; Guerini-Rocco E
J Clin Pathol; 2018 Sep; 71(9):767-773. PubMed ID: 29535211
[TBL] [Abstract][Full Text] [Related]
19. Molecular spectrum of TP53 mutations in plasma cell dyscrasias by next generation sequencing: an Italian cohort study and overview of the literature.
Lionetti M; Barbieri M; Manzoni M; Fabris S; Bandini C; Todoerti K; Nozza F; Rossi D; Musto P; Baldini L; Neri A
Oncotarget; 2016 Apr; 7(16):21353-61. PubMed ID: 26870891
[TBL] [Abstract][Full Text] [Related]
20. Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma.
Walker BA; Mavrommatis K; Wardell CP; Ashby TC; Bauer M; Davies FE; Rosenthal A; Wang H; Qu P; Hoering A; Samur M; Towfic F; Ortiz M; Flynt E; Yu Z; Yang Z; Rozelle D; Obenauer J; Trotter M; Auclair D; Keats J; Bolli N; Fulciniti M; Szalat R; Moreau P; Durie B; Stewart AK; Goldschmidt H; Raab MS; Einsele H; Sonneveld P; San Miguel J; Lonial S; Jackson GH; Anderson KC; Avet-Loiseau H; Munshi N; Thakurta A; Morgan GJ
Blood; 2018 Aug; 132(6):587-597. PubMed ID: 29884741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
